Gordan Freeman-PD-1 cancer immunotherapy

Watch this webinar on Labroots at www.labroots.co...
The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is immunosuppressive. Engagement of PD-1 by PD-L1 or PD-L2 results in attenuated TCR signaling and inhibition of T-cell immune functions. Tumors exploit these immune checkpoint pathways to evade immune eradication. Blockade of the PD-1, PD-L1, and CTLA-4 checkpoints is proving to be an effective and durable cancer immunotherapy in a subset of patients in a broad variety of tumor types by allowing the patient to produce an effective anti-tumor immune response. Expression of PD-L1 by tumor cells or infiltrating immune cells correlates with responsiveness to PD-1 or PD-L1 blockade but is an imperfect biomarker since some patients who do not express PD-L1 still respond. A broad range of other immune modulatory targets has been identified and are potential targets for synergizing with immune checkpoint blockade. Advances in understanding T cell coinhibitory pathways have stimulated a new era of immunotherapy with effective drugs to treat cancer.

[@aryanstanley3529]

Great talk. Nicely and concisely covered some of the basics, as well as further detail and future prospects.
Sound loses sync after around 50:25 (in between the talk and the Q&A). Otherwise, very nicely done. Thanks for uploading.

[@muffinman1]

Fantastic talk, very informative.

[@justsomeguywithoutbluehair4159]

Informative talk, but then Gordon starting hitting people with a crowbar and yelled about "the combine" and "black mesa".

[@laurataylor7709]

*wait, this isn’t half life*